Advertisement
News
Subscribe to MDT Magazine News

Qforma, Leading Provider of Healthcare Analytics, Announces Three New Appointments

January 31, 2011 5:35 am | by Bio-Medicine.Org | Comments

SANTA FE, N.M. and PRINCETON, N.J., Jan. 31, 2011 /- Qforma, the leading provider of advanced analytics and predictive modeling technologies for the health sciences industry, today announced the appointments of Ted Pine and Devon Reimer as Vice Presidents of Business Development, and...

TOPICS:

Bayer Animal Health Announces the Launch of Advantage® II and K9 Advantix® II

January 31, 2011 5:35 am | by Bio-Medicine.Org | Comments

SHAWNEE, Kan., Jan. 31, 2011 /- Bayer Animal Health announced this month at the North American Veterinary Conference, the availability of its new products:  Advantage® II for cats and dogs, and K9 Advantix® II for dogs.  These products combine the adulticidal...

TOPICS:

Amarin Provides 2010 Year-End Review to Shareholders

January 31, 2011 5:35 am | by Bio-Medicine.Org | Comments

DUBLIN and MYSTIC, Conn., Jan. 31, 2011 /- Amarin Corporation plc (Nasdaq: AMRN ), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today issued a special letter to its shareholders. The text of the letter, written by Joseph S. Zakrzewski, Executive...

TOPICS:
Advertisement

ClinOps to Change Name to Emphusion

January 31, 2011 5:35 am | by Bio-Medicine.Org | Comments

SAN FRANCISCO, Jan. 31, 2011 /- ClinOps is a specialized contract research organization with a core service offering combining expert data management, biostatistics and specialized clinical services. Emphusion targets development programs in biotechnology, medical device, and...

TOPICS:

Laureate Pharma Changes Name to Laureate Biopharmaceutical Services, Inc.

January 31, 2011 5:35 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J., Jan. 31, 2011 /- Laureate Pharma, Inc. has changed its name to Laureate Biopharmaceutical Services, Inc. (Laureate Biopharma) to better describe the company's positioning in the biopharmaceutical industry.  The company's logo has been updated to emphasize "Laureate"...

TOPICS:

Endologix Announces Favorable Clinical Results for Nellix Technology

January 31, 2011 5:34 am | by Bio-Medicine.Org | Comments

IRVINE, Calif., Jan. 31, 2011 /- Endologix, Inc. (Nasdaq: ELGX ), developer of minimally invasive treatments for aortic disorders, announced today the publication of favorable clinical results for the Nellix technology for the endovascular repair of abdominal aortic aneurysm (EVAR)....

TOPICS:

Mederi Therapeutics Announces Receipt of FDA 510(k) Clearance for the MDRF1 Radiofrequency Generator

January 31, 2011 5:34 am | by Bio-Medicine.Org | Comments

GREENWICH, Conn., Jan. 31, 2011 /- Mederi Therapeutics Inc. announced today that it has received FDA 510(k) clearance for its new MDRF1 Generator. The Mederi RF Generator powers the Stretta® System for treatment of Gastroesophageal Reflux Disease (GERD) as well as the Secca®...

TOPICS:

Johnson & Johnson Recall of DePuy Hip Devices: Lewitt Hackman Files Suit

January 31, 2011 5:34 am | by Bio-Medicine.Org | Comments

LOS ANGELES, Jan. 31, 2011 /- Attorneys at Lewitt, Hackman, Shapiro, Marshall & Harlan, a southern California law firm, filed a lawsuit regarding a Johnson & Johnson recall of DePuy metal on metal hip replacement devices. The firm filed the suit against DePuy Orthopedics, Inc. and...

TOPICS:
Advertisement

Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System

January 31, 2011 5:33 am | by Bio-Medicine.Org | Comments

NATICK, Mass., Jan. 31, 2011 /- Boston Scientific Corporation (NYSE: BSX ) today announced that the U.S. Food and Drug Administration (FDA) has approved its Renegade® HI-FLO™ Fathom® Pre-Loaded System for selective access and delivery of diagnostic, embolic and therapeutic...

TOPICS:

Case Western Reserve University presents revolutionary developments in using implantable diamond-coated devices at MEDCon, May 16-18th at Navy Pier in Chicago, IL

January 31, 2011 4:56 am | Comments

Medical Electronic Device Conference & Expo (MEDCon) announces that Christian Zorman, Professor of Electrical Engineering & Computer Science at Case Western, will present research findings on studies of implants made from diamonds and flexible polymers at the conference & expo being held in May 2011.

Vanda Pharmaceuticals Files Shelf Registration Statement

January 31, 2011 4:34 am | by Bio-Medicine.Org | Comments

ROCKVILLE, Md., Jan. 31, 2011 /- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA ), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced that it has filed a universal shelf registration statement on...

TOPICS:

New Monograph Spotlights Urgent Need for Congress to Get Neurotoxins and Other Poisons Out of Vaccines

January 31, 2011 4:33 am | by Bio-Medicine.Org | Comments

WASHINGTON, Jan. 31, 2011 /- With the latest round of flu vaccine damage surfacing in mid-January, the FDA is again investigating the association between vaccines and febrile seizures in children. How often do health consumers need the "wool pulled over their eyes" about vaccines? It's...

TOPICS:

Boston Scientific Announces FDA Approval of Renegade® HI-FLOâ„¢ Fathom® Pre-Loaded System

January 31, 2011 3:31 am | by Boston Scientific | Comments

New system integrates market-leading Renegade HI-FLO Microcatheter with high-torque Fathom-16 Steerable Guidewire for peripheral embolization procedures

TOPICS:

Functional Technologies Announces First Quarter 2011 Financial Results

January 31, 2011 2:45 am | by The Associated Press | Comments

http://www.functionaltechcorp.com () —Functional Technologies Corp. (TSX VENTURE: FEB) (the "Company") today reported operational and financial results for the first quarter ended November 30, 2010. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with...

Functional Technologies reports lower Q1 loss as operating expenses lower

January 31, 2011 2:45 am | by The Associated Press | Comments

Functional Technologies Corp. (TSXV:FEB) tightens first-quarter loss of $773,600 compared to $908,900 a year ago, as operating expenses were lowered to $896,700 in the period.

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading